Skip to main content
SpringerLink
Log in

Sitagliptin

A Viewpoint by Itamar Raz

  • Adis Drug Profiles
  • Guest Commentary
  • Published:
Drugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Turner RC. The UK Prospective Diabetes Study: a review. Diabetes Care 1998 Dec; 21 Suppl. 3: C35–8

    PubMed  Google Scholar 

  2. DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 2006; 368(9541): 1096–105

    Article  Google Scholar 

  3. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006 Dec; 29(12): 2638–43

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Diabetes Unit, Hadassah University Hospital, Jerusalem, Israel

    Itamar Raz

Authors
  1. Itamar Raz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Raz, I. Sitagliptin. Drugs 67, 598 (2007). https://doi.org/10.2165/00003495-200767040-00008

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200767040-00008

Search

Navigation